

1 **Article type:** Original Article

2 **Title:** Cutaneous immune-related adverse events are associated with longer overall survival in  
3 advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort study

4  
5 Shijia Zhang, MBI<sup>1,2\*</sup>, Kimberly Tang, BA<sup>1\*</sup>, Guihong Wan, PhD<sup>1,2\*</sup>, Nga Nguyen, MD, MPH<sup>1</sup>,  
6 Chenyue Lu, MBI<sup>1,2</sup>, Pearl Ugwu-Dike, BA<sup>1</sup>, Neel Raval, BA<sup>1</sup>, Jayhyun Seo, BA<sup>1</sup>, Nora A.  
7 Alexander, BS<sup>1</sup>, Ruple Jairath, BS<sup>1</sup>, Jordan Phillipps, BS<sup>1</sup>, Bonnie W. Leung, BSc<sup>1</sup>, Kathleen  
8 Roster, MS<sup>1</sup>, Wenxin Chen, BS<sup>1,2</sup>, Leyre Zubiri, MD, PhD<sup>3</sup>, Genevieve Boland, MD, PhD<sup>4</sup>,  
9 Steven T. Chen, MD, MPH<sup>1</sup>, Hensin Tsao, MD, PhD<sup>1</sup>, Shadmehr Demehri, MD, PhD<sup>1,5</sup>, Nicole  
10 R. LeBoeuf, MD, MPH<sup>6</sup>, Kerry L. Reynolds, MD<sup>3</sup>, Kun-Hsing Yu, MD, PhD<sup>2</sup>, Alexander  
11 Gusev, PhD<sup>7</sup>, Shawn G. Kwatra, MD<sup>8\*\*</sup>, and Yevgeniy R. Semenov, MD, MA<sup>1\*\*</sup>

12  
13 <sup>1</sup>Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston,  
14 MA

15 <sup>2</sup>Department of Biomedical Informatics, Harvard Medical School, Boston, MA

16 <sup>3</sup>Division of Oncology and Hematology, Department of Medicine, Massachusetts General  
17 Hospital, Harvard Medical School, Boston, MA

18 <sup>4</sup>Department of Surgery, Massachusetts General Hospital, Boston, MA

19 <sup>5</sup>Center for Cancer Immunology and Cutaneous Biology Research Center, Department of  
20 Dermatology, Center for Cancer Research, Massachusetts General Hospital Cancer Center,  
21 Massachusetts General Hospital and Harvard Medical School, Boston, MA

22 <sup>6</sup>Department of Dermatology, Center for Cutaneous Oncology, Dana-Farber Cancer Institute,  
23 Brigham and Women's Hospital, Harvard Medical School, Boston, MA

24 <sup>7</sup>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

25 <sup>8</sup>Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD

26  
27 \*designates co-first authors

28 \*\*designates co-senior authors

29  
30 **Twitter handle:** @EugeneSemenovMD

31  
32 **Corresponding author:**

33 Yevgeniy R. Semenov, MD, MA

34 Department of Dermatology

35 Massachusetts General Hospital

36 Harvard Medical School

37 40 Blossom Street

38 Bartlett Hall 6R, Room 626

39 Boston, MA 02114

40 Email: [ysemenov@mgh.harvard.edu](mailto:ysemenov@mgh.harvard.edu)

41  
42 **Reprint requests:** Yevgeniy R. Semenov, MD, MA

43  
44 **Funding sources:** YRS is supported in part by the Department of Defense under Award Number  
45 W81XWH2110819 and by the Dermatology Foundation under the Medical Dermatology Career  
46 Development Award. SGK is supported by the National Institute of Arthritis and

47 Musculoskeletal and Skin Diseases of the National Institutes of Health under Award Number  
48 K23AR077073. NRL is supported by NIH/NCI grant U54-CA225088. K-HY is supported in  
49 part by grant R35GM142879 from the National Institute of General Medical Sciences, NIH. The  
50 other authors received no funding for this research. The content is solely the responsibility of the  
51 authors and does not necessarily represent the official views of the funders.

52  
53 **Conflicts of interest:** YRS is an advisory board member/consultant and has received honoraria  
54 from Incyte Corporation, Castle Biosciences, Galderma, and Sanofi outside of the submitted  
55 work. SGK is an advisory board member/consultant for Abbvie, Celldex Therapeutics,  
56 Galderma, Incyte Corporation, Johnson & Johnson, Novartis Pharmaceuticals Corporation,  
57 Pfizer, Regeneron Pharmaceuticals, Sanofi, and Kiniksa Pharmaceuticals and has served as an  
58 investigator for Galderma, Kiniksa Pharmaceuticals, Pfizer Inc., and Sanofi. NRL is a consultant  
59 and has received honoraria from Bayer, Seattle Genetics, Sanofi, Silverback and Synox  
60 Therapeutics outside the submitted work.

61  
62 **IRB approval status:** Reviewed and exempted by Mass General Brigham IRB.

63  
64 **Patient consent on file:** N/A

65  
66 **Manuscript word count:** 2443 [max: 2,500]

67 **Capsule summary:** 49 [max: 50]

68 **Abstract word count:** 193 [max: 200]

69 **References:** 35

70 **Figures/Tables:** 5 [max: 5]

71 **Supplementary Figures/Tables:** 23

72 **Attachments:** STROBE checklist

73  
74 **Keywords:** immunotherapy; immune checkpoint inhibitor; immune-related adverse events;  
75 cutaneous adverse reactions; skin toxicity; mortality; melanoma; oncology

76

77 **Capsule Summary (max 50 words)**

- 78       • Patients on immune checkpoint inhibitors (ICIs) who developed cutaneous  
79       immune-related adverse events (irAEs) had favorable outcomes. This was  
80       especially notable for melanoma patients who had irAEs, both those with vitiligo  
81       and other morphologies.
- 82       • Development of irAEs in ICI-treated patients can be used to prognosticate  
83       survival and guide treatment decisions.

84 **Abstract (max 200 words)**

85 **Background:** Cutaneous immune-related adverse events (cirAEs) occur in up to 40% of immune  
86 checkpoint inhibitor (ICI) recipients. However, the association of cirAEs with survival remains  
87 unclear.

88 **Objective:** To investigate the association of cirAEs with survival among ICI recipients.

89 **Methods:** ICI recipients were identified from the Mass General Brigham healthcare system  
90 (MGB) and Dana-Farber Cancer Institute (DFCI). Patient charts were reviewed for cirAE  
91 development within 2 years after ICI initiation. Multivariate time-varying Cox proportional  
92 hazards models, adjusted for age, sex, race/ethnicity, Charlson Comorbidity Index, ICI type,  
93 cancer type, and year of ICI initiation were utilized to investigate the impact of cirAE  
94 development on overall survival.

95 **Results:** Of the 3,731 ICI recipients, 18.1% developed a cirAE. 6-month landmark analysis and  
96 time-varying Cox proportional hazards models demonstrated that patients who developed cirAEs  
97 were associated with decreased mortality (HR=0.87,p=0.027), particularly in melanoma patients  
98 (HR=0.67,p=0.003). Among individual morphologies, lichenoid eruption (HR=0.51,p<0.001),  
99 psoriasiform eruption (HR=0.52,p=0.005), vitiligo (HR=0.29,p=0.007), isolated pruritus without  
100 visible manifestation of rash (HR=0.71,p=0.007), acneiform eruption (HR =0.34,p=0.025), and  
101 non-specific rash (HR=0.68, p<0.001) were significantly associated with better survival after  
102 multiple comparisons adjustment.

103 **Limitations:** Retrospective design; single geography.

104 **Conclusion:** CirAE development is associated with improved survival among ICI recipients,  
105 especially melanoma patients.

106

## 107 **Introduction**

108 Immune checkpoint inhibitors (ICIs) have transformed cancer care over the past decade.  
109 Checkpoint proteins are membrane-bound markers that bind T-cell partner proteins to induce  
110 energy<sup>1</sup>. ICIs block these interactions, strengthening endogenous immune responses against  
111 tumors. Currently-approved therapies target Programmed cell death protein 1 (PD-1) and its  
112 ligand (PD-L1) or Cytotoxic T-lymphocyte protein 4 (CTLA-4)<sup>1</sup>. As of 2022, 9 ICIs were  
113 approved and with expansion to different targets and cancers, the percentage of cancer patients  
114 eligible for ICIs has increased from 1.54% in 2011 to 43.6% in 2020<sup>2,3</sup>.

115 Immune activity alterations from ICI can manifest as immune-related adverse events  
116 (irAEs), necessitating informed management guidelines<sup>4</sup>. Most common and least lethal irAEs  
117 affect the skin and gastrointestinal tract, whereas rarer but more serious irAEs affect the  
118 cardiovascular and central nervous systems. Notably, cutaneous irAEs (cirAEs), the most  
119 common toxicities, occur in up to 40% of recipients and can be potential low-grade biomarkers  
120 of therapeutic effect<sup>5</sup>.

121 Though early reports have associated irAE development with improved ICI response,  
122 studies examining individual contributions of cirAEs to predicting outcomes are limited to  
123 single-institutional observational studies with small sample size and absence of appropriate  
124 control populations<sup>6,7</sup>. A recent study from our group utilized population-level claims-based  
125 databases to investigate outcomes among patients with cirAEs, identifying significantly increased  
126 survival<sup>8</sup>. However, this was limited by diagnostic uncertainty in cirAE definitions. Therefore, in  
127 this study we examine overall and morphology-specific survival implications of cirAE  
128 development among ICI recipients using a large-scale multi-institutional clinical registry with  
129 manual cirAE phenotyping. We seek to provide necessary confirmatory data on the clinical  
130 implications of these toxicities, which will inform treatment decisions and patient counseling.

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152 **Methods**

153 Cohort Determination

154 Cancer patients receiving ICI at Massachusetts General Hospital, Brigham and Women's  
155 Hospital, and Dana-Farber Cancer Institute between December 1, 2011 and October 30, 2020  
156 were included. Patients were excluded if records were incomplete for variables of interest. A  
157 flowchart is in **Figure 1**.

#### 158 Data Extraction

159 Research Patient Data Registry (RPDR)<sup>9</sup> and Enterprise Data Warehouse (EDW) are institutional  
160 clinical databases in the Mass General Brigham (MGB) Healthcare System. RPDR contains  
161 multimodal clinical information: basic demographics, International Classification of Diseases  
162 (ICD) codes, and lab results. EDW provides detailed documentation of all ICI administrations.  
163 Patient age, sex, race/ethnicity, cancer type, ICD codes, date of death or last follow-up were  
164 extracted. Due to small sample sizes among some races/ethnicities, this variable was categorized  
165 into White, Asian, Black, (non-white) Hispanic, and other. ICD codes from all visits were used to  
166 calculate Charlson Comorbidity Index (CCI) score at ICI initiation<sup>10</sup>. EDW was used to ascertain  
167 time and class of ICI received. ICIs were separated into anti-PD-1 (pembrolizumab, nivolumab,  
168 cemiplimab), anti-PD-L1 (atezolizumab, avelumab, durvalumab), anti-CTLA-4 (ipilimumab),  
169 and combination therapy (CTLA-4 and either PD-1 or PD-L1 inhibition).

#### 170 Chart Review

171 Manual chart review was conducted by two independent reviewers to ascertain cirAE presence,  
172 timing, and morphology following ICI initiation. Suspected events were categorized and graded  
173 using Common Terminology Criteria for Adverse Events version 5.0<sup>11</sup>. For each patient who  
174 developed a cutaneous eruption following ICI, a likelihood score was assigned on a scale of 1  
175 (highly unlikely) to 4 (highly likely). The likelihood of cirAE was determined by review of rash  
176 timing, morphology, absence of competing risk factors, histologic confirmation when available,

177 and response to treatment of the eruption. Patients who achieved likelihood scores of 3 and 4  
178 were categorized as having a cirAE. If concordance was not achieved, a third reviewer arbitrated  
179 the cases. Further details are provided in **Supplemental Methods**.

#### 180 Statistical Analyses

181 We used Pearson's chi-squared or Fisher exact test for categorical variables and t-test or Kruskal-  
182 Wallis test for continuous variables. Kaplan-Meier curves were utilized to investigate differences  
183 in survival between patients with and without cirAEs. For patients with no known mortality  
184 information, their last system encounters were their censoring dates. We performed landmark  
185 survival analyses and time-varying Cox proportional hazards regression modeling, adjusting for  
186 age, sex, race/ethnicity, CCI, ICI type, cancer type, and year of ICI initiation to account for  
187 guarantee-time bias<sup>12</sup>. Guarantee-time bias occurs when exposure of interest competes with risk  
188 of mortality (e.g., patients must be alive long enough to be able to develop a cirAE). Not  
189 controlling for this would bias the model in favor of longer survival in the cirAE cohort. To  
190 account for this, we performed a landmark analysis, assessing exposure (e.g., cirAE status)  
191 before the given landmark time and excluding patients with the outcome of interest (e.g.,  
192 mortality) prior to the landmark<sup>13</sup>. A survival model was then utilized on this restricted  
193 population to evaluate the relationship between exposure and outcome. Sensitivity analyses were  
194 performed around landmark times: 3-, 6-, 9-, and 12-months following ICI initiation. Another  
195 control for guarantee-time bias is utilizing time-varying Cox proportional hazards regression  
196 modeling, which uses the exposure as a time-dependent covariate; subjects are classified as  
197 unexposed until the start of cirAE and exposed thereafter<sup>14</sup>. This model has the advantage of  
198 incorporating all study follow-up data since the analysis begins at the time of cohort entry.  
199 Therefore, this method has increased statistical power over the landmark method<sup>15</sup>. Lastly,

200 because all patients in this cohort had metastatic cancer, the CCI was rescaled to exclude cancer  
201 diagnoses. The analyses were repeated for individual cancer types and cirAE morphologies. All  
202 statistical analyses were conducted in R statistical software version 3.6.1.

## 203 **Results**

204 A total of 3,731 ICI recipients were identified. Patient characteristics are shown in **Table**  
205 **1**. Between cirAE and non-cirAE groups, there were no significant differences in median age at  
206 ICI initiation (65.1 vs 65.4 years), mean CCI score (3.30 vs 3.64), and sex (42.9% vs 46.0%  
207 female). Compared to the non-cirAE group, the cirAE group had longer duration of follow-up  
208 (913 vs 385 days), higher proportion of white patients (93.8% vs 90.4%), higher proportion of  
209 combination immunotherapy utilization (17.8 % vs 8.5 %), and higher proportion of melanoma  
210 patients (35.7% vs 17.1%), all which were statistically significant. **Table 2** demonstrates the  
211 distribution of cirAE morphologies among all cancer, melanoma, and non-melanoma patients.

212 Multivariate time-varying Cox proportional hazards models (**Table 3**) demonstrated that  
213 patients with cirAEs were significantly associated with better survival when analyzed across all  
214 cancer indications (HR=0.87, p=0.027). No differences in mortality by race/ethnicity or sex  
215 were noted. Independent of cirAE development, patients with gastrointestinal malignancies  
216 (HR=1.32, p<0.001) had worse outcomes than thoracic cancer patients, while patients with  
217 melanoma (HR=0.44, p<0.001) and genitourinary cancer (HR=0.79, p=0.002) had better  
218 survival. To explore the contribution of ICI-induced vitiligo, a further analysis categorized  
219 patients into those who developed vitiligo and non-vitiligo cirAEs (**eFigures 1a and 1b**),  
220 demonstrating that both groups were significantly associated with decreased mortality compared  
221 to patients without cirAEs among all ICI recipients and melanoma patients. On average, patients  
222 who developed cirAEs survived 320 days (10.5 months) longer than those who did not.

223 To explore the association of cirAEs with each cancer type, we performed multivariate  
224 time-varying Cox proportional hazards models restricting the population to patients with a  
225 specific malignancy (**eTables 1**). Here, association of cirAEs with good prognosis was strongest

226 among melanoma patients (HR=0.67, p=0.003) (**eTable 2**). CirAEs were not significantly  
227 associated with mortality when restricting to thoracic, gastrointestinal, genitourinary, head and  
228 neck, and other cancers individually. When grouping all non-melanoma cancers, there was a  
229 weak association that did not reach statistical significance (**eTable 3**).

230         These analyses were repeated using a landmark approach. A 6-month landmark was  
231 utilized for the primary model as most cirAEs occurred by this time (**eTable 4**)<sup>15</sup>. Sensitivity  
232 analyses were performed using 3-, 9-, and 12- months as alternative landmark times (**eTable 5-**  
233 **8**). As before, patients who developed cirAEs demonstrated significant survival advantage using  
234 landmark times of 3 months (HR=0.75,p<0.001) and 6 months (HR=0.83,p=0.006), with better  
235 survival at 9 months (HR=0.89,p=0.11) and 12 months (HR=0.94,p=0.5) which did not reach  
236 statistical significance. Additionally, we conducted the same landmark and sensitivity analyses  
237 among melanoma patients, as this is where the association of cirAEs was strongest in the time-  
238 varying Cox models (**eTable 9-12**). Among these patients, cirAE development was associated  
239 with significantly lower risk of mortality at 3 months (HR=0.65,p=0.002), 6 months  
240 (HR=0.65,p=0.003), 9 months (HR=0.64,p=0.004), and 1 year (HR=0.68,p=0.021) as landmark  
241 times.

242         We next investigated the adjusted survival impact of individual cirAE morphologies  
243 (**Table 4**). Compared with the non-cirAE group, almost all morphologies were associated with  
244 better survival. Specifically, rash (HR=0.68, p<0.001), lichenoid eruption (HR=0.51,p<0.001),  
245 psoriasiform eruption (HR=0.52,p =0.005), vitiligo (HR=0.29,p=0.007), isolated pruritus without  
246 visible manifestations of rash (HR=0.71,p=0.007), and acneiform eruption(HR=0.34,p=0.025)  
247 remained significantly associated with better survival after Benjamini-Hochberg (BH) correction

248 (eTables 13-19). Eczematous eruption (HR = 0.71, p=0.056) was borderline significantly  
249 associated.

## 250 **Discussion**

251           Though irAEs have been shown to be important indicators of ICI efficacy, their  
252 association with mortality is a growing field of interest<sup>16-21</sup>. This large-scale retrospective study  
253 investigates the association of cirAEs with mortality outcomes among ICI-treated cancer patients  
254 using expert-phenotyped cirAE status. We demonstrate that cirAE development after ICI  
255 initiation is an important prognostic indicator of response to ICI, particularly among melanoma  
256 patients.

257           CirAEs occurred in 18% of ICI recipients in contrast to clinical trial reports of cirAEs  
258 occurring in up to 40% of patients. This may be from cirAE overdiagnosis in clinical trials,  
259 which typically lack rigorous phenotyping. Additionally, cirAEs reported in observational studies  
260 are usually symptomatic enough to require clinical evaluation, whereas cirAEs reported in  
261 clinical trials may be mild. The latter group is unlikely detected in real-world observational data  
262 as patients may not present for evaluation, thus, explaining this discrepancy.

263           Overall, our study suggests that cirAE development is associated with a 13% reduction in  
264 mortality, with patients developing cirAEs living on average 10.5 months longer than those who  
265 did not. The association of cirAEs with increased survival identified here is consistent with our  
266 prior population-level findings (using algorithmic rather than manual cirAE curation done here),  
267 which demonstrated a 19-23% statistically significant risk reduction in mortality among patients  
268 with cirAEs<sup>8</sup>. The overall similar conclusions reached by these different analytical approaches  
269 with completely independent cohorts provide additional rigor to our study findings. Additionally,  
270 almost all cirAE morphologies were associated with better survival, with isolated pruritus  
271 without visible manifestation of rash, rash, lichenoid eruption, psoriasiform eruption, acneiform  
272 eruption and vitiligo demonstrating the most significant correlation: 29%, 32%, 49%, 48%, 66%

273 and 71% reduction in mortality, respectively. These findings are important as cirAEs are among  
274 the earliest events to occur following ICI initiation and could therefore be early predictive  
275 biomarkers of therapeutic response.

276 When stratifying by cancer type, the association of cirAEs with improved survival was  
277 strongest in patients with melanoma. Restricting the population to melanoma patients, those who  
278 developed cirAEs had a 33% decreased risk of mortality compared to those who did not. We  
279 speculate that the survival improvement seen among melanoma patients may be explained by  
280 melanoma's high tumor mutational burden<sup>22-23</sup> as previous studies have demonstrated that high  
281 levels of immunogenic neoantigens in melanoma is correlated with increased response to anti-  
282 PD-1 and better survival<sup>22-23</sup>. This may also trigger reactivity to similar skin antigens,  
283 contributing to cirAE development and better outcomes. But for most individual cancers, cirAEs  
284 were not significantly correlated. Excluding melanoma and examining all non-melanoma cancers  
285 as a group demonstrated weak clinical protection of cirAEs that ceased to remain statistically  
286 significant.

287 Due to the melanoma cohort's strong signal, we performed subgroup analyses of  
288 individual cirAE morphologies among melanoma patients showing that both vitiligo and non-  
289 vitiligo cirAEs are associated with significantly longer survival. Though previous studies  
290 identified vitiligo as associated with decreased mortality among melanoma patients, we show that  
291 other morphologies of cirAEs are also associated with better outcomes in comparison to patients  
292 without cirAEs<sup>24-26</sup>. Even after excluding vitiligo, cirAE development remains associated with  
293 better survival among all ICI recipients and melanoma patients specifically. Landmark analyses  
294 performed yielded similar conclusions, even after sensitivity analyses around landmark time-

295 3-,6-, 9-, and 12-months. Notably, lichenoid eruption demonstrated significant association with  
296 increased survival that surpassed that of vitiligo in the setting of melanoma.

297 A possible explanation for the association of vitiligo development with better survival in  
298 melanoma is epitope spreading. This develops when immune responses against primary epitopes  
299 spread to other distinct epitopes in the same tissue type<sup>27-30</sup>. This results in clonal diversification  
300 of T-cell responses, proving to be beneficial in cancer treatment. When expansion of reactivity  
301 occurs toward tumor antigens, it enhances the ICI efficacy<sup>29-30</sup>. We hypothesize that this  
302 phenomenon is responsible for development of vitiligo when T-cells to melanoma antigens  
303 respond inappropriately to new epitopes on normal melanocytes<sup>27-30</sup>. Because epitope spreading  
304 contributes to robust antitumor activity, this may explain the increased survival among ICI  
305 recipients with melanoma who develop vitiligo when compared to those who do not, particularly  
306 due to expected shared melanocyte antigens.

307 However, the development of other cirAEs among melanoma patients that confer  
308 comparable correlation with better survival than vitiligo, leads us to believe that cirAE  
309 development in the setting of melanoma may not be entirely driven by epitope spreading. Studies  
310 have suggested that systemic induction of the immune response by ICIs may re-activate pre-  
311 existing T-cells, which originally developed against melanocytes at the onset of melanoma<sup>30</sup>.  
312 Systemic memory T-cells can express receptors important in the return of these circulating  
313 lymphocytes to the original tissue of activation,<sup>31-33</sup> manifesting as cirAEs. This idea of tissue  
314 homing suggests that tumor tissue source is an important variable in generation of irAEs, and the  
315 interaction between prognostically favorable cirAE morphologies and tumor tissue type may  
316 uncover mechanistic insights into immunotherapy response.

317           This study is limited by retrospective design. Patients may not be representative as they  
318 were drawn from two tertiary care cancer centers. Differences in clinical judgment may exist  
319 between physicians who documented notes and medically trained researchers who extracted  
320 information from charts. To adjust for inter-rater biases, cirAE status was ascertained by two  
321 independent reviewers. Cases that did not meet concordance were evaluated by a board-certified  
322 dermatologist with expertise in immunotherapy toxicities (YRS). To account for immortal time  
323 and selection bias, landmark analyses and time-varying Cox proportional hazards models were  
324 used to provide a more rigorous approach.

325           Although there are studies analyzing the association of irAEs with mortality, we  
326 demonstrate significantly favorable outcomes in ICI-treated patients who develop cirAEs, with  
327 enhanced protection in melanoma patients. We find cirAEs to be associated with increased  
328 survival as a group and additionally, significantly improved prognosis is observed among other  
329 morphologies in addition to vitiligo. Together, this suggests that cirAE development after ICI is a  
330 key prognostic indicator of survival. This is important in guiding oncologists and dermatologists  
331 in managing cirAEs and counseling patients about the prognostic implications of these toxicities.  
332 Further studies should investigate interactions between management of toxicities and survival  
333 and underlying biologic mechanisms for development of these favorable events and their  
334 interaction with immunotherapy response.

335 **Acknowledgements:** We thank Stacey Duey from Partners Scientific Computing for her help in  
336 extracting RPDR patient data.

337 **References**

- 338 1. He X, Xu C. Immune checkpoint signaling and cancer immunotherapy. *Cell research*.  
339 2020;30(8):660-669.
- 340 2. Jamal S, Hudson M, Fifi-Mah A, Ye C. Immune-related adverse events associated with  
341 cancer immunotherapy: a review for the practicing rheumatologist. *The Journal of*  
342 *rheumatology*. 2020;47(2):166-175.
- 343 3. Haslam A, Gill J, Prasad V. Estimation of the percentage of US patients with cancer who  
344 are eligible for immune checkpoint inhibitor drugs. *JAMA network open*.  
345 2020;3(3):e200423–e200423.
- 346 4. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse  
347 events in patients treated with immune checkpoint inhibitor therapy: American Society of  
348 Clinical Oncology Clinical Practice Guideline. *Journal of clinical oncology: official*  
349 *journal of the American Society of Clinical Oncology*. 2018;36(17):1714.
- 350 5. Thompson LL, Krasnow NA, Chang MS, et al. Patterns of cutaneous and noncutaneous  
351 immune-related adverse events among patients with advanced cancer. *JAMA dermatology*.  
352 2021;157(5):577-582.
- 353 6. Hirotsu KE, Scott MKD, Marquez C, et al. Histologic subtype of cutaneous immune-  
354 related adverse events predicts overall survival in patients receiving immune checkpoint  
355 inhibitors. *J Am Acad Dermatol*. 2021 Dec 4:S0190-9622(21)02922-4. doi:  
356 10.1016/j.jaad.2021.11.050. Epub ahead of print. PMID: 34875301.
- 357 7. Otto TS, Chang MS, Thompson LL, Chen ST. Limitations of morphology-based  
358 management for immune checkpoint inhibitor-related cutaneous adverse events. *J Am*

- 359 Acad Dermatol. 2021 Jun;84(6):e281-e282. doi: 10.1016/j.jaad.2021.01.054. Epub 2021  
360 Jan 23. PMID: 33493573.
- 361 8. Tang K, Seo J, Tiu BC, et al. Association of Cutaneous Immune-Related Adverse Events  
362 With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and  
363 Anti-Programmed Cell Death Ligand 1 Therapy. *JAMA Dermatol*. 2022 Feb  
364 1;158(2):189-193. doi: 10.1001/jamadermatol.2021.5476. PMID: 35019948; PMCID:  
365 PMC8756357.
- 366 9. Nalichowski R, Keogh D, Chueh HC, Murphy SN. Calculating the benefits of a Research  
367 Patient Data Repository. *AMIA . Annual Symposium proceedings AMIA Symposium*.  
368 Published online 20068.
- 369 10. Hall WH, Ramachandran R, Narayan S, Jani AB, Vijayakumar S. An electronic  
370 application for rapidly calculating Charlson comorbidity score. *BMC Cancer*. 2004;4:94.  
371 Published 2004 Dec 20. doi:10.1186/1471-2407-4-94
- 372 11. “Common Terminology Criteria for Adverse Events (CTCAE).” *Cancer Therapy*  
373 *Evaluation Program (CTEP)*, National Cancer Institute, 21 Sept. 2020,  
374 [https://ctep.cancer.gov/protocolDevelopment/electronic\\_applications/ctc.htm](https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm).
- 375 12. Lévesque LE, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in cohort  
376 studies: example using statins for preventing progression of diabetes. *Bmj*. 2010;340.
- 377 13. Gleiss A, Oberbauer R, Heinze G. An unjustified benefit: immortal time bias in the  
378 analysis of time-dependent events. *Transpl Int*. 2018 Feb;31(2):125-130. doi:  
379 10.1111/tri.13081. Epub 2017 Nov 9. PMID: 29024071.

- 380 14. Zhang Z, Reinikainen J, Adeleke KA, Pieterse ME, Groothuis-Oudshoorn CGM. Time-  
381 varying covariates and coefficients in Cox regression models. *Ann Transl Med*.  
382 2018;6(7):121. doi:10.21037/atm.2018.02.12
- 383 15. Cho, I.S., Chae, Y.R., Kim, J.H. *et al*. Statistical methods for elimination of guarantee-  
384 time bias in cohort studies: a simulation study. *BMC Med Res Methodol* **17**, 126 (2017).  
385 <https://doi.org/10.1186/s12874-017-0405-6>
- 386 16. Wongvibulsin S, Pahalyants V, Kalinich M, et al. Epidemiology and risk factors for the  
387 development of cutaneous toxicities in patients treated with immune checkpoint inhibitors:  
388 A United States population-level analysis. *J Am Acad Dermatol*. Published online 2021:1-  
389 10.
- 390 17. Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune  
391 checkpoint inhibitors. *J Immunother Cancer*. 2019 Nov 15;7(1):306. doi: 10.1186/s40425-  
392 019-0805-8. PMID: 31730012; PMCID: PMC6858629.
- 393 18. Albandar, Heidar J et al. “Immune-Related Adverse Events (irAE) in Cancer Immune  
394 Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or  
395 Not?.” *Cancers* vol. 13,5 989. 27 Feb. 2021, doi:10.3390/cancers13050989
- 396 19. Petrelli F, Grizzi G, Ghidini M, et al. Immune-related Adverse Events and Survival in  
397 Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and  
398 Meta-Analysis. *Journal of immunotherapy (Hagerstown, Md : 1997)*. 2020;43(1).  
399 doi:10.1097/CJI.0000000000000300
- 400 20. Street S, Chute D, Strohschein I, et al. The positive effect of immune checkpoint inhibitor-  
401 induced thyroiditis on overall survival accounting for immortal time bias: a retrospective

- 402 cohort study of 6596 patients. *Annals of Oncology*. 2021;32(8).  
403 doi:10.1016/j.annonc.2021.05.357
- 404 21. Burke KP, Grebinoski S, Sharpe AH, Vignali DAA. Understanding adverse events of  
405 immunotherapy: A mechanistic perspective. *J Exp Med*. 2021 Jan 4;218(1):e20192179.  
406 doi: 10.1084/jem.20192179. PMID: 33601411; PMCID: PMC7754677.
- 407 22. Strickler JH, Hanks BA, Khasraw M. Tumor Mutational Burden as a Predictor of  
408 Immunotherapy Response: Is More Always Better? *Clin Cancer Res*. 2021 Mar  
409 1;27(5):1236-1241. doi: 10.1158/1078-0432.CCR-20-3054. Epub 2020 Nov 16. PMID:  
410 33199494
- 411 23. Kim SI, Cassella CR, Byrne KT. Tumor Burden and Immunotherapy: Impact on Immune  
412 Infiltration and Therapeutic Outcomes. *Front Immunol*. 2021 Feb 1;11:629722. doi:  
413 10.3389/fimmu.2020.629722. PMID: 33597954; PMCID: PMC7882695.
- 414 24. Matsuya T, Nakamura Y, Matsushita S, Tanaka R, Teramoto Y, Asami Y, et al. Vitiligo  
415 expansion and extent correlate with durable response in anti-programmed death 1  
416 antibody treatment for advanced melanoma: A multi-institutional retrospective study. *J*  
417 *Dermatol*. 2020 Jun;47(6):629-635. doi: 10.1111/1346-8138.15345. Epub 2020 Apr 10.  
418 PMID: 32275100.
- 419 25. Nakamura Y, Tanaka R, Asami Y, Teramoto Y, Imamura T, Sato S, et al. Correlation  
420 between vitiligo occurrence and clinical benefit in advanced melanoma patients treated  
421 with nivolumab: A multi-institutional retrospective study. *J Dermatol*. 2017  
422 Feb;44(2):117-122. doi: 10.1111/1346-8138.13520. Epub 2016 Aug 11. PMID: 27510892.
- 423 26. Teulings HE, Limpens J, Jansen SN, Zwinderman AH, Reitsma JB, Spuls PI, et al.  
424 Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving

- 425 immunotherapy and its association with survival: a systematic review and meta-analysis. *J*  
426 *Clin Oncol*. 2015 Mar 1;33(7):773-81. doi: 10.1200/JCO.2014.57.4756. Epub 2015 Jan  
427 20. PMID: 25605840.
- 428 27. Brossart P. The Role of Antigen Spreading in the Efficacy of Immunotherapies. *Clin*  
429 *Cancer Res*. 2020 Sep 1;26(17):4442-4447. doi: 10.1158/1078-0432.CCR-20-0305. Epub  
430 2020 May 1. PMID: 32357962.
- 431 28. Hardwick N, Chain B. Epitope spreading contributes to effective immunotherapy in  
432 metastatic melanoma patients. *Immunotherapy*. 2011 Jun;3(6):731-3. doi:  
433 10.2217/imt.11.62. PMID: 21668310.
- 434 29. Lo JA, Kawakubo M, Juneja VR, Su MY, Erlich TH, LaFleur MW, et al. Epitope  
435 spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune  
436 checkpoint blockade responses. *Sci Transl Med*. 2021 Feb 17;13(581):eabd8636. doi:  
437 10.1126/scitranslmed.abd8636. PMID: 33597266; PMCID: PMC8130008.
- 438 30. Chan LS, Vanderlugt CJ, Hashimoto T, Nishikawa T, Zone JJ, Black MM, et al. Epitope  
439 spreading: lessons from autoimmune skin diseases. *J Invest Dermatol*. 1998  
440 Feb;110(2):103-9. doi: 10.1046/j.1523-1747.1998.00107.x. PMID: 9457902.
- 441 31. Campbell JJ, Haraldsen G, Pan J, Rottman J, Qin S, Ponath P, et al. The chemokine  
442 receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells.  
443 *Nature*. 1999 Aug 19;400(6746):776-80. doi: 10.1038/23495. PMID: 10466728.
- 444 32. Fuhlbrigge RC, Kieffer JD, Armerding D, Kupper TS. Cutaneous lymphocyte antigen is a  
445 specialized form of PSGL-1 expressed on skin-homing T cells. *Nature*. 1997 Oct  
446 30;389(6654):978-81. doi: 10.1038/40166. PMID: 9353122.

- 447 33. Jiang X, Clark RA, Liu L, Wagers AJ, Fuhlbrigge RC, Kupper TS. Skin infection  
448 generates non-migratory memory CD8+ T(RM) cells providing global skin immunity.  
449 Nature. 2012 Feb 29;483(7388):227-31. doi: 10.1038/nature10851. PMID: 22388819;  
450 PMCID: PMC3437663.
- 451 34. Chen S, LeBoeuf N, Reynolds K, Semenov Y. 1263 Dermatologic immune related adverse  
452 event disease definitions: a multi-institutional Delphi consensus project presented on  
453 behalf of the oncodermatology working group. vol 10. 2022:A1309-A1309.
- 454 35. Cohen, J. (1960). A Coefficient of Agreement for Nominal Scales. Educational and  
455 Psychological Measurement, 20(1), 37–46. <https://doi.org/10.1177/001316446002000104>  
456  
457  
458

459

**Figure 1. Study Design Flowchart**

Attached as separate jpeg file in accordance with the JAAD submission checklist

**Table 1.** Baseline Characteristics for Cancer Patients Treated with ICI

<b>Characteristic</b>	<b>CirAE (N=676)</b>	<b>No CirAE (N=3055)</b>	<b>P- value</b>
<b>Sex</b>			
Female	290 (42.9%)	1405 (46.0%)	0.156
Male	386 (57.1%)	1650 (54.0%)	
<b>Charlson Comorbidity Index</b>			
Median [IQR <sup>a</sup> ]	3.00 [2.00]	3.00 [3.00]	<0.001
Mean[SD]	3.30[2.33]	3.64[2.42]	
<b>Age at ICI Initiation</b>			
Median [IQR]	65.1 [16.5]	65.4 [16.4]	0.695
<b>Year of ICI Initiation</b>			
Median [IQR]	2017 [2.00]	2017 [2.00]	0.338
<b>Days of Follow-up</b>			
Median [IQR]	913 [952]	385 [906]	<0.001
<b>Race/Ethnicity</b>			
White	634 (93.8%)	2763 (90.4%)	0.008
Asian	25 (3.7%)	106 (3.5%)	
Black or African American	8 (1.2%)	83 (2.7%)	
Hispanic	2 (0.3%)	21 (0.7%)	
Other/Unknown	7 (1.0%)	82 (2.7%)	
<b>Cancer Type</b>			
Melanoma	241 (35.7%)	522 (17.1%)	<0.001
Thoracic	125 (18.5%)	1000 (32.7%)	
Gastrointestinal	66 (9.8%)	350 (11.5%)	
Genitourinary	88 (13.0%)	303 (9.9%)	
Brain/Nervous System	13 (1.9%)	130 (4.3%)	
Breast	28 (4.1%)	95 (3.1%)	
Gynecologic	24 (3.6%)	183 (6.0%)	
Head and Neck	60 (8.9%)	270 (8.8%)	
Hematologic	14 (2.1%)	147 (4.8%)	
Non-melanoma skin	10 (1.5%)	25 (0.8%)	
Sarcoma	7 (1.0%)	30 (1.0%)	
<b>ICI Type</b>			
PD-1	470 (69.5%)	2350 (76.9%)	<0.001
Combination Therapy	120 (17.8%)	261 (8.5%)	
PD-L1	65 (9.6%)	381 (12.5%)	
CTLA-4	21 (3.1%)	63 (2.1%)	
<b>Mortality Status</b>			
Alive	337 (49.9%)	1182 (38.7%)	<0.001

Deceased	339 (50.1%)	1873 (61.3%)
----------	-------------	--------------

<sup>a</sup>IQR= Interquartile Range

460  
461  
462

**Table 2:** Distribution of CirAE Morphologies in All Cancer, Melanoma, and Other Cancer Patients

Cutaneous Diagnosis	All Cancer (N=676)	Melanoma (N=241)	Other Cancer* (N=435)	P-value
Acneiform Eruption	13 (1.9%)	5 (2.1%)	8 (1.8%)	
Bullous Eruption	17 (2.5%)	6 (2.5%)	11 (2.5%)	
Drug Hypersensitivity NOS	32 (4.7%)	14 (5.8%)	18 (4.1%)	
Eczematous Eruption	41 (6.1%)	11 (4.6%)	30 (6.9%)	
Erythema-multiforme-like Eruption	4 (0.6%)	2 (0.8%)	2 (0.5%)	
Isolated Pruritus without visible manifestation of rash	90 (13.3%)	35 (14.6%)	55 (12.6%)	
Lichenoid Eruption	52 (7.7%)	10 (4.1%)	42 (9.7%)	<0.001
Maculopapular Eruption	121 (17.9%)	56 (23.2%)	65 (14.9%)	
Mucositis	9 (1.3%)	1 (0.4%)	8 (1.8%)	
Panniculitis	3 (0.4%)	1 (0.4%)	2 (0.5%)	
Psoriasiform Eruption	30 (4.4%)	8 (3.3%)	22 (5.1%)	
Rash NOS	222 (32.8%)	74 (30.8%)	148 (34.0%)	
SJS/TEN-like Eruption	4 (0.6%)	1 (0.4%)	3 (0.7%)	
Vitiligo	22 (3.3%)	17 (7.1%)	5 (1.1%)	
Alopecia	1 (0.1%)	0 (0%)	1 (0.2%)	
DRESS	1 (0.1%)	0 (0%)	1 (0.2%)	
Follicular Eruption	5 (0.7%)	0 (0%)	5 (1.1%)	
Sweet's Syndrome	3 (0.4%)	0 (0%)	3 (0.7%)	
Urticarial Eruption	6 (0.9%)	0 (0%)	6 (1.4%)	

463  
464  
465  
466  
467  
468  
469

\*Other cancer includes: thoracic, gastrointestinal, genitourinary, brain/nervous system, breast, gynecologic, head and neck, hematologic, non-melanoma skin cancer, and sarcoma.

**Table 3:** Association between CirAE with Overall Survival Using a Multivariate Time-varying Cox Proportional Hazards Model

<b>Characteristic</b>	<b>Hazard Ratio</b>	<b>95% Confidence Interval</b>	<b>P-value</b>
<b>CirAE</b>	0.87	0.79, 0.98	0.027
<b>Sex</b>			
Female	Ref <sup>a</sup>	Ref	
Male	1.04	0.95, 1.13	0.4
<b>Age at ICI Initiation</b>	1.00	0.99, 1.00	0.4
<b>Charlson Comorbidity Index</b>	1.09	1.07, 1.11	<0.001
<b>Race/Ethnicity</b>			
White	Ref	Ref	
Asian	1.08	0.86, 1.36	0.5
Black	0.90	0.69, 1.18	0.4
Hispanic	1.02	0.60, 1.74	>0.9
Other/Unknown	0.84	0.62, 1.14	0.3
<b>Cancer Type</b>			
Thoracic	Ref	Ref	
Melanoma	0.44	0.38, 0.51	<0.001
Gastrointestinal	1.32	1.15, 1.51	<0.001
Genitourinary	0.79	0.68, 0.92	0.002
Other*	0.94	0.84, 1.05	0.3
<b>ICI Type</b>			
CTLA-4	Ref	Ref	
Combination Therapy	1.22	0.88, 1.69	0.2
PD-1	0.94	0.69, 1.27	0.7
PD-L1	0.77	0.55, 1.09	0.12
<b>Year of ICI Initiation</b>	1.05	1.01, 1.09	0.014

<sup>a</sup>Ref= Reference group

\*Other includes: brain/nervous system, breast, gynecologic, head and neck, hematologic, non-melanoma skin cancer, and sarcoma

470  
471  
472  
473  
474  
475  
476  
477  
478  
479

480

**Table 4:** Association of CirAE Morphology with Overall Survival

<b>Cutaneous Morphology<sup>a</sup></b>	<b>Hazard Ratio</b>	<b>95% Confidence Interval</b>	<b>P-value<sup>b</sup></b>
Vitiligo	0.29	0.12, 0.71	0.007*
Acneiform Eruption	0.34	0.13, 0.87	0.025*
Lichenoid Eruption	0.51	0.36, 0.73	<0.001*
Psoriasiform Eruption	0.52	0.33, 0.82	0.005*
Rash NOS	0.68	0.57, 0.81	<0.001*
Isolated Pruritus Without Visible Manifestation of Rash	0.71	0.55, 0.91	0.007*
Eczematous Eruption	0.71	0.50, 1.01	0.056
Drug Hypersensitivity NOS	0.79	0.52, 1.21	0.3
Maculopapular Eruption	0.82	0.66, 1.03	0.084
Bullous Eruption	0.87	0.45, 1.68	0.7
Other CirAE Morphologies	0.98	0.64, 1.50	>0.9

481 <sup>a</sup>Each row corresponds to a separate multivariable time-varying Cox proportional hazards model  
482 for the association of cirAE morphology with overall survival by comparison to patients without  
483 cirAEs, adjusting for age at ICI initiation, gender, race, CCI, cancer type, ICI type, and year of  
484 ICI initiation.

485 <sup>b</sup>P-values that remain significant after Benjamini-Hochberg multiple comparison adjustment are  
486 marked with an asterisk.

487

Received ICI at Partners Healthcare between December 1, 2011 and October 30, 2020 (n=3776)

Data Collection:  
a) Whether cutaneous eruption developed after ICI;  
b) If so, how likely the cutaneous eruption was due to ICI (scale: 1-4);  
c) If CirAE, characterize morphology of the cutaneous eruption;  
d) Other relevant variables

Excluded (n=45):

a) Incomplete records (n=43)  
b) No followup after ICI initiation (n=2)

Patients analyzed  
(n=3,731)

CirAE group

Non-CirAE control group

CirAE (n=676):  
developed cutaneous eruption due to ICI (high likelihood: 3 or 4)

Non-CirAE (n=3,055):  
a) No cutaneous eruption after ICI (n=2877), or  
b) Low likelihood of cutaneous eruption due to ICI < 3 (n=173)